Circulating cytokeratin-18 and tumour necrosis factor-α in patients with alcoholic liver cirrhosis
More details
Hide details
Department of Internal Diseases, Medical University of Lublin, Poland
Department of Family Medicine, Medical University of Lublin, Poland
Individual Medical Practice, Lublin, Poland
Department of Mathematics and Medical Biostatistics, Medical University of Lublin, Poland
Department of Medical Chemistry, Medical University of Lublin
Department of Trauma Surgery and Emergency Medicine, Medical University of Lublin, Poland
Department of Ethics and Human Philosophy, Medical University of Lublin, Poland
Paweł Kiciński   

Department of Family Medicine, Medical University, Staszica 11, 20-081 Lublin, Poland
J Pre Clin Clin Res. 2016;10(2):87–90
The aim of the study was to assess the usefulness of TNF-α and CK-18 as diagnostic markers of alcoholic liver cirrhosis. Additionally, the effects of the stage of liver cirrhosis on concentrations of TNF-α and CK-18, as well as their correlation, were evaluated.

Material and Methods:
Sixty-two patients with alcoholic liver cirrhosis treated in various hospitals were randomly enrolled. The stage of cirrhosis was assessed according to the Child-Turcotte-Pugh scoring system. The control group consisted of 31 healthy people without liver disease. Concentrations of TNF-α and cytokeratin-18 in blood plasma of patients and controls were measured using the sandwich enzyme immunoassay technique, with commercially available quantitative ELISA test kits

The concentration of CK-18 was statistically higher in patients with alcoholic liver cirrhosis, compared to the control group. The concentration of TNF-α was significantly higher in patients with alcoholic liver cirrhosis, compared to the control group. Higher concentrations of TNF-α were found only in patients with stage C and B alcoholic liver cirrhosis, compared to healthy persons.

The levels of TNF-α and total CK-18 were higher in patients with alcoholic liver cirrhosis than in healthy individuals. No correlation was found between the level of CK-18 and stage of liver cirrhosis.

Zatoński W, Sułkowska U, Mańczuk M, et al. Liver Cirrhosis Mortality in Europe, with Special Attention to Central and Eastern Europe. Eur Addict Res. 2010;16: 193–201.
Schuppan D, Afdhal N. Liver Cirrhosis. Lancet 2008; 371: 838–51.
Olaso E, Friedman S. Molecular regulation of hepatic fibrogenesis. J Hepatol. 1998; 29: 836–47.
Rath P, Aggarwal B. TNF-induced signaling in apoptosis. J Clin Immunol. 1999; 19: 350–64.
Ustaalioglu B, Bilici A, Ercan S, et al. The prognostic importance of changing serum M30 and M65 values after chemotherapy in patients with advanced-stage non-small-cell lung cancer. Med Oncol. 2013; 30: 551.
Hagg M, Biven K, Ueno T, et al. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest New Drugs. 2002; 20: 253–9.
Szabo G, Mandrekar P, Dolganiuc A. Innate immune response and hepatic inflammation. Semin Liver Dis. 2007; 27: 339–50.
Bemelmans M, van Tits L, Buurman W. Tumour necrosis factor: function, release and clearance. Crit Rev Immunol. 1996; 16: 1–11.
Liu J. Ethanol and liver: recent insights into the mechanisms of ethanol-induced fatty liver. World J Gastroenterol. 2014; 20: 14672–85.
Jen-Eing T, Jung-Fa C, Lee-Yea H, et al. Tumour necrosis factor-α 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma. Neoplasia 2007; 9: 987–92.
Giannelli G, Antonaci S. Immunological and molecular aspects of liver fibrosis in chronic hepatitis C virus infection. Histol Histopathol. 2005; 20: 939–44.
Bataller R, Brenner D. Liver fibrosis. J Clin Invest. 2005; 115: 209–18.
Balkwill F. Cancer and the chemokine network. Nat Rev Cancer. 2004; 4: 540–50.
Daniluk J, Szuster-Ciesielska A, Drabko J, et al. Serum cytokine levels in alcohol-related liver cirrhosis. Alcohol. 2001; 23: 29–34.
Shiraki M, Terakura Y, Iwasa J, et al. Elevated serum tumour necrosis factor-a and soluble tumour necrosis factor receptors correlate with aberrant energy metabolism in liver cirrhosis. Nutrition. 2010; 26: 269–75.
Niknejad H, Khayat-Khoei M, Peirovi H, et al. Human amniotic epithelial cells induce apoptosis of cancer cells: a new anti-tumour therapeutic strategy. Cytotherapy 2014; 16: 33–40.
Canbay A, FeldsteinA, Kronenberger B, et al. Cytokeratin 18 as marker for non-invasive diagnosis and prognosis of acute and chronic liver diseases. Z Gastroenterol. 2014; 52: 290–5.
Yildiz I, Tas F, Kilic L, et al. A high serum level of M65 is associated with tumour aggressiveness and an unfavourable prognosis for epithelial ovarian cancer. Cancer Chemother Pharmacol. 2013; 72: 437–44.
Kar P, Malik P. Prognostic Value of Serum Apoptosis Markers CK 18 [M30 and M65] in Acute Liver Failure. J Clin Exp Hepatol. 2014; 4(suppl. 2): S1–2.
Gonzalez-Quintela A, García J, Campos J, et al. Serum cytokeratins in alcoholic liver disease: contrasting levels of cytokeratin-18 and cytokeratin-19. Alcohol. 2006; 38: 45–9.
Mueller S, Seitz H, Rausch V. () Non-invasive diagnosis of alcoholic liver disease. World J Gastroenterol. 2014; 20: 14626–41.
Joka D, Wahl K, Moeller S, et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatol. 2012; 55: 455–64.
Lavallard V, Bonnafous S, Patouraux S, et al. Serum Markers of Hepatocyte Death and Apoptosis Are Non Invasive Biomarkers of Severe Fibrosis in Patients with Alcoholic Liver Disease. PLoS ONE 2011; 6: e17599. doi:10.1371/journal.pone.0017599.
Wieckowska A, Zein N, Yerian L, et al. In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease. Hepatol. 2006; 44: 27–33.
Ding G, Li Z, Zhang L, et al. Circulating full-length cytokeratin 18 for predicting prognosis of hepatitis B virus-related acute-on-chronic liver failure patients with lamivudine treatment. Hepatol Res. 2016; 46(4): 329–334. doi: 10.1111/hepr.12549.